Kazia Therapeutics (Kazia Therapeutics) COGS-to-Revenue : 0.00 (As of Jun. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Kazia Therapeutics COGS-to-Revenue?

Kazia Therapeutics's Cost of Goods Sold for the six months ended in Jun. 2023 was $0.00 Mil. Its Revenue for the six months ended in Jun. 2023 was $0.00 Mil.

Kazia Therapeutics's COGS to Revenue for the six months ended in Jun. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Kazia Therapeutics's Gross Margin % for the six months ended in Jun. 2023 was N/A%.

Kazia Therapeutics COGS-to-Revenue Historical Data

The historical data trend for Kazia Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics COGS-to-Revenue Chart

Kazia Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

COGS-to-Revenue

Get a 7-Day Free Trial

Kazia Therapeutics Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Kazia Therapeutics COGS-to-Revenue Calculation

Kazia Therapeutics's COGS to Revenue for the fiscal year that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Kazia Therapeutics's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Kazia Therapeutics (NAS:KZIA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Kazia Therapeutics's Gross Margin % for the six months ended in Jun. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Kazia Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Kazia Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Kazia Therapeutics (Kazia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (NAS:KZIA) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000

Website

https://www.kaziatherapeutics.com

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Executives

Josiah T Austin	director, 10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204
El Coronado Holdings, Llc	10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204